GARDASIL 9 Human Papillomavirus 9-Valent Vaccine

GARDASIL 9 represents a significant advancement in the field of immunology and public health, offering robust protection against nine strains of the human papillomavirus (HPV). This vaccine is meticulously designed to induce an immune response against the HPV types that are most commonly associated with cervical, vulvar, vaginal, and anal cancers, as well as genital warts.

Product Specifications:
- Type: Recombinant vaccine
- Valency: 9-valent, targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58
- Formulation: Each 0.5 mL dose contains purified inactive proteins from HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58
- Preservative: None
- Storage: Refrigerated at 2°C to 8°C (36°F to 46°F)
- Shelf Life: Check the packaging for the expiration date
- Administration: Intramuscular injection, typically administered in a 2- or 3-dose schedule

Common Applications and User Groups:
- Adolescents: Both male and female, starting from ages 9 to 14, as part of routine immunization schedules
- Young Adults: Up to age 26 for catch-up vaccination programs
- At-Risk Populations: Individuals with compromised immune systems or increased risk of HPV-related diseases

Supplier Overview - Seqirus Australia:
Seqirus Australia is a prominent player in the global biotechnology field, specializing in the development and manufacturing of innovative immunological solutions. As a subsidiary of CSL Limited, Seqirus is part of the second-largest influenza vaccine provider in the world and has a rich heritage in safeguarding public health.

Authority in Vaccine Production:
- Innovation: Seqirus is at the forefront of vaccine technology, including the use of MF59 adjuvant and cell-based production methods.
- Quality Assurance: Adherence to stringent quality control and safety standards ensures the reliability of their vaccines.
- Global Reach: With a broad distribution network, Seqirus ensures the availability of vaccines like GARDASIL®9 to a wide range of demographics.
- Commitment to Public Health: Seqirus's dedication to preventing disease and protecting life is evidenced by their extensive portfolio of vaccines and their active role in pandemic preparedness.
Seqirus Australia's expertise in the vaccine space, combined with their commitment to innovation and quality, positions them as a trusted authority in the provision of GARDASIL®9 and other essential vaccines. Their ongoing research and development efforts continue to contribute to the global fight against infectious diseases, including HPV.